← All trials
NCT07171840
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2021
- Primary completion
- Jul 23, 2022
- Completion date
- Dec 23, 2022
- First posted
- Sep 15, 2025
- Last posted
- Sep 26, 2025
- Enrollment
- 43
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Humanitas UniversityLead sponsor
- Humanitas UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.